Target Information

Target General Infomation
Target ID
T96721
Former ID
TTDS00339
Target Name
Vascular endothelial growth factor
Synonyms
VEGF; Vascular endothelial cell growth factor
Target Type
Successful
Disease Adult primary hepatocellular carcinoma [ICD10: C22]
Breast cancer [ICD9: 174, 175; ICD10: C50]
Cancer [ICD9: 140-229; ICD10: C00-C96]
Lymphoma; Non-hodgkin's lymphoma [ICD9: 200, 202, 202.8; ICD10: C81-C86, C82-C85]
Metastatic breast cancer [ICD10: C50]
Multiple myeloma [ICD9: 203; ICD10: C90]
Non-small cell lung cancer [ICD10: C33-C34]
Non-small cell lung cancer; Metastatic colorectal cancer [ICD9:153, 154; ICD10: C33-C34, C18-C21]
Recurrent squamous cell carcinoma of the hypopharynx [ICD10: D37]
Target Validation
T96721
Drugs and Mode of Action
Drug(s) Avastin+/-Tarceva Drug Info Phase 3 Non-small cell lung cancer [551595]
Bevacizumab + Erlotinib Drug Info Phase 3 Non-small cell lung cancer; Metastatic colorectal cancer [553819], [554242]
Bevacizumab + Rituximab Drug Info Phase 3 Lymphoma; Non-hodgkin's lymphoma [522045]
Bevacizumab + Trastuzumab Drug Info Phase 3 Metastatic breast cancer [532301]
Bevacizumab + Erlotinib Drug Info Phase 2 Adult primary hepatocellular carcinoma [523055], [553932], [554003], [555115], [555445], [555446]
Bevacizumab + Trastuzumab Drug Info Phase 2 Breast cancer [554002]
Bevacizumab + Erlotinib Drug Info Phase 1/2 Recurrent squamous cell carcinoma of the hypopharynx [553734]
AT001/r84 Drug Info Phase 1 Cancer [550216]
Inhibitor Avastin+/-Tarceva Drug Info [550797], [550798]
Bevacizumab + Erlotinib Drug Info [551607]
Bevacizumab + Rituximab Drug Info [551607]
Bevacizumab + Trastuzumab Drug Info [551607]
BIBF100 Drug Info [537114]
References
Ref 522045ClinicalTrials.gov (NCT00486759) A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma. U.S. National Institutes of Health.
Ref 523055ClinicalTrials.gov (NCT01130519) A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer. U.S. National Institutes of Health.
Ref 532301AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013 May 10;31(14):1719-25.
Ref 551595Clinical pipeline report, company report or official report of Roche.
Ref 553734ClinicalTrials.gov (NCT00055913) Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Ref 553819ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Ref 553932ClinicalTrials.gov (NCT00287222) Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
Ref 554002ClinicalTrials.gov (NCT00365365) Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
Ref 554003ClinicalTrials.gov (NCT00365391) Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
Ref 554242ClinicalTrials.gov (NCT00598156) Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva
Ref 555115ClinicalTrials.gov (NCT02655536) Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
Ref 555445Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S17-23. doi: 10.3816/CLC.2009.s.003.
Ref 555446Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011 May 28;377(9780):1846-54. doi: 10.1016/S0140-6736(11)60545-X.
Ref 537114Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
Ref 550797Clinical pipeline report, company report or official report of Genentech (2009).
Ref 550798Clinical pipeline report, company report or official report of Genentech (2009).
Ref 551607Clinical pipeline report, company report or official report of Roche (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.